Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Feinböck, C; Luger, A; Klingler, A; Egger, T; Bielesz, GK; Winkler, F; Siebenhofer, A; Grossschädl, F; Frank, E; Irsigler, K; Austrian Glimepiride Study Group.
Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone.
Diabetes Nutr Metab. 2003; 16(4):214-221
Web of Science
PubMed
- Co-Autor*innen der Med Uni Graz
- Lueger Andreas
- Siebenhofer-Kroitzsch Andrea
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- AIM: To determine the efficacy of, and compliance with, glimepiride or acarbose in patients with Type 2 diabetes. METHODS: Two hundred and nineteen patients with Type 2 diabetes uncontrolled by diet alone were randomized to receive either glimepiride (1, 2, 3, 4 or 6 mg once daily, n = 111) or acarbose (50, 100, 150 or 200 mg 3 times daily, n = 108). Both drugs were titrated in a 6-week dose-finding phase to achieve a fasting blood glucose (FBG) concentration < or = 7.8 mmol/ (140 mg/dl). Patients achieving this target entered a 20-week treatment period. Efficacy was assessed by responder rate, number of patients achieving a FBG of < or = 7.8 mmol/l, HbA1c, blood glucose concentrations in response to a standard breakfast, body weight and compliance. RESULTS: Glimepiride was associated with a significantly greater responder rate than acarbose (61 vs 34%, p < 0.001), significantly greater decreases in HbA1c (2.5 +/- 2.2% vs 1.8 +/- 2.2%, p = 0.014) and FBG (2.6 +/- 2.6 mmol/l vs 1.4 +/- 2.8 mmo/l, p = 0.004), a decreased glucose response to breakfast compared with acarbose [area under curve (AUC) end: 8.9 +/- 2.7 mmol/l vs 11.3 +/- 3.9 mmol/l, p = 0.0001], and was accompanied by significantly greater compliance (91 < or = 12% vs 66 +/- 26%, p = 0.0001). Weight loss during the study was observed in both the acarbose group (1.9 +/- 3.9 kg, p = 0.001) and glimepiride group [0.4 +/- 5.2 kg, p = 0.8 (NS)]. CONCLUSIONS: Improved efficacy and greater compliance were observed in response to treatment with glimepiride compared with acarbose, in patients with Type 2 diabetes.
- Find related publications in this database (using NLM MeSH Indexing)
- Acarbose - therapeutic use
- Aged - therapeutic use
- Blood Glucose - analysis
- C-Peptide - blood
- Diabetes Mellitus, Type 2 - diet therapy
- Fasting - diet therapy
- Female - diet therapy
- Hemoglobin A, Glycosylated - analysis
- Humans - analysis
- Hypoglycemic Agents - therapeutic use
- Male - therapeutic use
- Middle Aged - therapeutic use
- Patient Compliance - therapeutic use
- Sulfonylurea Compounds - therapeutic use
- Find related publications in this database (Keywords)
- Type 2 diabetes
- glimepiride
- acarbose